Recurrent Glioblastoma Treatment: State of the Art and Future Perspectives in the Precision Medicine Era.

Although the primary endpoint of efficacy was not achieved at a 15-month follow-up, the combined administration showed a positive trend with regard to survival at longer follow-up times (28.7 months), with a statistically significant difference in OS between the two arms (hazard ratio, 0.66) and corneal epitheliopathy being reported as the most common adverse effect (25% of cases). 4.4.

also in 11,005 other papers